Le Lézard
Classified in: Health
Subjects: PET, MAT

CV Sciences, Inc. Expands +PlusCBD Pet Product Offerings with the Launch of Pet Chews


Pet Hip and Joint Health Chews and Pet Calming Care Chews improve the physical and emotional well-being of dogs

SAN DIEGO, March 26, 2024 /PRNewswire/ -- CV Sciences, Inc. (OTCQB: CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, proudly announces its latest innovation and product launch: a premier CBD chew tailored for pets, +PlusCBDtm Pet Hip and Joint Health Chews and +PlusCBDtm Pet Calming Care Chews. +PlusCBDtmPet wellness treats are crafted with the utmost care and supported by extensive research, and are now further validated by a landmark safety study backed by the National Animal Supplement Council (NASC). NASC is the leading trade association advocating for the health and wellness of companion animals that are given health supplements by their owners. The latest additions to the industry-leading +PlusCBD lineup are now available nationwide at select retailers and from our website at www.pluscbdoil.com.

The pet wellness industry has witnessed a growing demand for natural alternatives to support pets' overall well-being. In response to this need, +PlusCBDtmPet has developed a premium CBD chew with the mission of providing the highest quality ingredients and best-in-class health and nutrition for cherished family members - our pets. These formulas utilize the therapeutic properties of cannabidiol (CBD) derived from organic hemp plants. Along with CBD, our chews incorporate a curated selection of antioxidants, anti-inflammatory agents, and vital supplements designed to enhance the well-being of your loving companion. While one in five dogs deal with joint pain, +PlusCBD Pet Hip and Joint Health Chews pairs premium THC-free hemp extract with Glucosamine, Turmeric, Rosehips, and Ginger Root providing relief for pets grappling with age-related stiffness or discomfort from physical activity. Similarly, more than 70% of dogs exhibit at least one anxiety-related behavior or habit. The non-GMO, THC-free +PlusCBD Pet Calming Care Chew employs a vitamin-rich formula of Chamomile, L-Tryptophan, Ginger Root, and L-Theanine, offering respite from anxiety and stress triggered by various stimuli such as separation, loud noises, or environmental changes, fostering a sense of relaxation and well-being in your devoted pet. Each CBD chew undergoes rigorous testing by independent laboratories to ensure purity, potency, and compliance with NASC's stringent quality standards. With a THC-free formulation and non-psychoactive properties, our chews offer a safe and effective solution for pet owners seeking natural alternatives for their companions.

Joseph Dowling, CEO of CV Sciences, commented on the significance of the NASC safety study, stating, "The NASC's comprehensive safety study further validates CBD supplements to promote the health and wellness of our family pets. Our long-standing commitment to quality and safety will provide pet owners with products they can trust. We are immensely proud to offer CBD chews that not only meet our rigorous standards, but also exceed industry benchmarks for safety and efficacy."

+PlusCBDtm Pet Hip and Joint Health Chews and Pet Calming Care Chews are the first new offerings from CV Sciences in 2024. In 2023, the award-winning wellness brand introduced several product offerings designed to elevate the health and well-being of our human consumers, including +PlusCBDtm Reserve Collection Extra Gummies, +PlusCBDtm Reserve Collection Sleep Gummies, +PlusCBDtm Daily Balance THC-Free Gummies and Softgels and +PlusCBDtm Reserve Collection Softgels. The continued expansion of the Company's industry-leading product catalog amplifies its commitment to providing all users, both two-legged and four, with research-supported, plant-based health and wellness alternatives. For more information, please visit +PlusCBD or CV Sciences.

About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB:CVSI) is a consumer wellness company specializing in nutraceuticals and plant-based foods. The Company's hemp extracts and other proven, science-backed, natural ingredients and products are sold through a range of sales channels from B2B to B2C. The Company's +PlusCBDtm branded products are sold at select retail locations throughout the U.S. and are the top-selling brands of hemp extracts in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry.   With a commitment to science, +PlusCBDtm product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov.  +PlusCBDtm was the first hemp extract supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. The Company's Cultured Foodstm brand provides a variety of 100% plant-based food products. Committed to crafting nutritious and flavorful alternatives, Cultured Foodstm caters to individuals seeking vegan, gluten-free, or flexitarian options for a wholesome and satisfying culinary experience. CV Sciences, Inc. has primary offices and facilities in San Diego, California, and Warsaw, Poland. The Company also operates a drug development program focused on developing and commercializing CBD-based novel therapeutics. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.

Media Contact:
Alexis Isaacs
[email protected] 

SOURCE CV Sciences, Inc.


These press releases may also interest you

at 05:05
MiLaboratories, a leader in RNA immune technologies, and Miltenyi Biotec, a global pioneer in biotechnology, are excited to announce a landmark partnership that promises to revolutionize the field of next-generation therapies. This collaboration...

at 05:02
Immunovia AB (publ) today announced that the Annual Report for 2023 has been published.  The annual report can be downloaded in pdf format and is available on Immunovia's website: https://investor.immunovia.com/financial-reports-presentations/. For...

at 04:19
Medivir AB (STO: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that an abstract for the combination of fostroxacitabine bralpamide (fostrox) + Lenvima® in...

at 04:15
Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced the expansion of its LV Edge System with the launch of a fully stable cell line development service. There are now two ways for customers to...

at 04:07
Huma Therapeutics ("Huma"), a leader in global digital health innovation, together with Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the launch of their innovative bladder cancer treatment companion app in...

at 04:00
Calibre Scientific is pleased to announce the acquisition of Camlab Limited ("Camlab" or the "Company"), a UK-based supplier of scientific equipment, chemicals, consumables, labware, and other laboratory supplies and services to customers in the...



News published on and distributed by: